Last reviewed · How we verify
Usual dopaminergic per os treatment
Usual dopaminergic per os treatment is a Dopamine agonist Small molecule drug developed by Rennes University Hospital. It is currently in Phase 3 development for Parkinson's disease, Prostate cancer.
Activates dopaminergic receptors to increase dopamine levels in the brain.
Activates dopaminergic receptors to increase dopamine levels in the brain. Used for Parkinson's disease, Prostate cancer.
At a glance
| Generic name | Usual dopaminergic per os treatment |
|---|---|
| Sponsor | Rennes University Hospital |
| Drug class | Dopamine agonist |
| Target | Dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
This is achieved through the activation of dopamine receptors, which helps to improve symptoms of Parkinson's disease and other movement disorders. The exact mechanism is not fully understood, but it is thought to involve the stimulation of dopamine release and/or the inhibition of dopamine reuptake.
Approved indications
- Parkinson's disease
- Prostate cancer
Common side effects
- Nausea
- Dizziness
- Headache
- Fatigue
- Dyspepsia
Key clinical trials
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Short and Long-term Responses of PD Symptoms to Earstim (NA)
- Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment (PHASE4)
- Dopaminergic RestauratIon by IntraVEntriculaire Administration (PHASE1, PHASE2)
- Relapse Prevention in Stimulant Use Disorder (EARLY_PHASE1)
- Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson's Disease (PHASE3)
- Multi-Strategy Intervention for Anesthesia Care of Obese Patients A Factorial Randomized Controlled Trial (NA)
- PRolaCT - Three Prolactinoma RCTs (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Usual dopaminergic per os treatment CI brief — competitive landscape report
- Usual dopaminergic per os treatment updates RSS · CI watch RSS
- Rennes University Hospital portfolio CI
Frequently asked questions about Usual dopaminergic per os treatment
What is Usual dopaminergic per os treatment?
How does Usual dopaminergic per os treatment work?
What is Usual dopaminergic per os treatment used for?
Who makes Usual dopaminergic per os treatment?
What drug class is Usual dopaminergic per os treatment in?
What development phase is Usual dopaminergic per os treatment in?
What are the side effects of Usual dopaminergic per os treatment?
What does Usual dopaminergic per os treatment target?
Related
- Drug class: All Dopamine agonist drugs
- Target: All drugs targeting Dopamine receptor
- Manufacturer: Rennes University Hospital — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Parkinson's disease
- Indication: Drugs for Prostate cancer
- Compare: Usual dopaminergic per os treatment vs similar drugs
- Pricing: Usual dopaminergic per os treatment cost, discount & access